Advancing novel, small molecule treatments targeting epigenetic mechanisms in tumor and immune cells for the benefit of patients

Constellation Pharmaceuticals (NASDAQ: CNST) is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

February 22, 2019
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences

February 20, 2019
Constellation Pharmaceuticals Announces Appointment to Board of Directors

January 3, 2019
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

Read More News

Associated Team Members

Robert Tepper, M.D.

Neil Exter

Craig Muir
Partner/Chief Technology Officer